| Symbol | PBYI |
|---|---|
| Name | PUMA BIOTECHNOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 10880 WILSHIRE BLVD., LOS ANGELES, CA 90024 |
| Telephone | (424) 248-6500 |
| Fax | — |
| — | |
| Website | https://www.pumabiotechnology.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001401667 |
| Description | Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Additional info from NASDAQ: |
2026-07-06 20:56
📋 AUERBACH ALAN H (Officer) plans to sell 44K shares of PUMA BIOTECHNOLOGY, INC. (at $8.26 each, total $364K) Filed: Jul 06, 2026 | ID: 005126
Read more
2026-07-06 20:49
📋 HUNT DOUGLAS M (Officer) plans to sell 8K shares of PUMA BIOTECHNOLOGY, INC. (at $8.26 each, total $70K) Filed: Jul 06, 2026 | ID: 005123
Read more
2026-07-06 20:44
📋 NOUGUES MAXIMO F (Officer) plans to sell 9K shares of PUMA BIOTECHNOLOGY, INC. (at $8.26 each, total $78K) Filed: Jul 06, 2026 | ID: 005121
Read more
2026-07-02 21:03
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-16 20:06
(99% Neutral) PUMA BIOTECHNOLOGY, INC. (PBYI) Announces Regulatory Update
Read more
2026-06-16 00:16
Director WILSON TROY EDWARD 🟡 adjusted position in 16.2K shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 Transaction Date: Jun 11, 2026 | Filing ID: 020709
Read more
2026-06-16 00:14
Director Stuglik Brian M 🟡 adjusted position in 18.9K shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 Transaction Date: Jun 11, 2026 | Filing ID: 020708
Read more
2026-06-16 00:13
Director Senderowicz Adrian 🟡 adjusted position in 0 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 Transaction Date: Jun 11, 2026 | Filing ID: 020706
Read more
2026-06-16 00:12
Director MILLER MICHAEL PATRICK 🟢 acquired 27.0K shares of PUMA BIOTECHNOLOGY, INC. (PBYI) Transaction Date: Jun 11, 2026 | Filing ID: 020705
Read more
2026-06-16 00:09
Director Dorval Allison 🟡 adjusted position in 15.4K shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 Transaction Date: Jun 11, 2026 | Filing ID: 020703
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07465757 | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SC… | Phase2 | Small Cell Lung Cancer ( SCLC ) | Not_Yet_Recruiting | 2026-09-30 | 2028-09-30 | ClinicalTrials.gov |
| NCT06369285 | A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-… | Phase2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | Recruiting | 2024-11-19 | 2028-12-31 | ClinicalTrials.gov |
| NCT05919108 | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Phase2 | Anatomic Stage I Breast Cancer | Recruiting | 2024-05-30 | 2031-04-30 | ClinicalTrials.gov |
| NCT06095505 | A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase2 | Small Cell Lung Cancer | Recruiting | 2024-02-08 | 2028-04-30 | ClinicalTrials.gov |
| NCT06109467 | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Ga… | Phase2 | GastroEsophageal Cancer | Active_Not_Recruiting | 2024-01-12 | 2028-04-01 | ClinicalTrials.gov |
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treate… | Phase2 | Early-stage Breast Cancer | Active_Not_Recruiting | 2022-08-31 | 2030-01-01 | ClinicalTrials.gov |
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-P… | Phase2 | Breast Cancer | Recruiting | 2022-07-21 | 2027-07-21 | ClinicalTrials.gov |
| NCT05274048 | Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer P… | Phase1 | Gastric Cancer | Recruiting | 2022-06-24 | 2027-06-01 | ClinicalTrials.gov |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase2 | Metastatic Prostate Adenocarcinoma | Withdrawn | 2021-05-21 | 2021-09-24 | ClinicalTrials.gov |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advan… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2020-08-24 | 2027-10-31 | ClinicalTrials.gov |
| NCT04366713 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast … | Phase2 | HER2 Amplified Breast Cancer | Completed | 2020-06-30 | 2021-12-28 | ClinicalTrials.gov |
| NCT04085315 | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Phase1 | Lung Cancer Metastatic | Recruiting | 2019-11-12 | 2026-12-31 | ClinicalTrials.gov |
| NCT03919292 | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutat… | Phase1 | Solid Tumor, Adult | Suspended | 2019-05-01 | 2031-01-31 | ClinicalTrials.gov |
| NCT03786107 | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations… | — | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer | Terminated | 2019-03-14 | 2021-01-21 | ClinicalTrials.gov |
| NCT03094052 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer… | Phase2 | HER2-positive Breast Cancer | Completed | 2018-10-09 | 2022-10-31 | ClinicalTrials.gov |
| NCT03457896 | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/… | Phase2 | Metastatic Colorectal Cancer | Unknown | 2018-05-18 | 2022-09-30 | ClinicalTrials.gov |
| NCT03377387 | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Posit… | Phase1 | Breast Cancer | Active_Not_Recruiting | 2017-12-13 | 2026-12-01 | ClinicalTrials.gov |
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer | Phase2 | Breast Cancer | Terminated | 2017-10-25 | 2021-07-20 | ClinicalTrials.gov |
| NCT02400476 | An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in P… | Phase2 | Early Stage HER2+ Breast Cancer | Completed | 2015-02-01 | 2021-04-22 | ClinicalTrials.gov |
| NCT02236000 | A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-… | Phase1 | Breast Cancer | Completed | 2014-08-01 | 2021-08-01 | ClinicalTrials.gov |
| NCT02334501 | Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects | Phase1 | Healthy | Completed | 2014-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic H… | Phase2 | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | Terminated | 2013-09-30 | 2023-01-02 | ClinicalTrials.gov |
| NCT01827267 | Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutat… | Phase2 | HER2-mutant Non-Small Cell Lung Cancer | Completed | 2013-07-01 | 2017-10-06 | ClinicalTrials.gov |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Pa… | Phase3 | HER2+ Metastatic Breast Cancer (MBC) | Completed | 2013-03-29 | 2019-12-09 | ClinicalTrials.gov |
| NCT01670877 | Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Brea… | Phase2 | Breast Neoplasms | Completed | 2012-12-11 | 2021-03-11 | ClinicalTrials.gov |
| NCT00932464 | Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Nerat… | Phase1 | Healthy | Withdrawn | 2012-08-01 | 2012-08-01 | ClinicalTrials.gov |
| NCT01494662 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | Phase2 | Breast Cancer | Completed | 2012-02-01 | 2024-04-19 | ClinicalTrials.gov |
| NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or … | Phase2 | Breast Cancer | Completed | 2010-10-01 | 2016-11-25 | ClinicalTrials.gov |
| NCT01142063 | A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects | — | Healthy | Completed | 2010-06-01 | 2010-09-01 | ClinicalTrials.gov |
| NCT01128842 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | Phase1 | Advanced Malignant Solid Tumors | Completed | 2010-04-01 | 2011-03-01 | ClinicalTrials.gov |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Trip… | Phase1 | Breast Cancer | Completed | 2010-04-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In Er… | Phase2 | Breast Cancer | Completed | 2009-08-21 | 2018-06-28 | ClinicalTrials.gov |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women W… | Phase3 | Breast Cancer | Completed | 2009-07-09 | 2019-10-04 | ClinicalTrials.gov |
| NCT00958724 | Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Adv… | Phase1 | Advanced Malignant Solid Tumors | Completed | 2009-07-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00781430 | Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subject… | Phase1 | Hepatic Insufficiency | Completed | 2009-04-01 | 2010-02-01 | ClinicalTrials.gov |
| NCT00864487 | Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Ne… | Phase1 | Healthy Subjects | Completed | 2009-04-01 | 2009-05-01 | ClinicalTrials.gov |
| NCT00860223 | Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pha… | Phase1 | Healthy | Completed | 2009-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00838539 | Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With So… | Phase1 | Neoplasms | Completed | 2009-04-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positiv… | Phase2 | Advanced Breast Cancer | Completed | 2009-02-04 | 2018-06-03 | ClinicalTrials.gov |
| NCT00814060 | Study Evaluating TwoTablet Formulations of Neratinib (HKI-272) | Phase1 | Healthy Subjects | Completed | 2009-01-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00741260 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors … | Phase1 | Breast Cancer | Completed | 2008-12-09 | 2018-06-01 | ClinicalTrials.gov |
| NCT00768469 | Study Evaluating Safety And Tolerability, Solid Tumor | Phase1 | Advanced Malignant Solid Tumors | Completed | 2008-10-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT00757809 | Study Evaluating The Tolerability Of Multiple Doses Of HKI-272 | Phase1 | Healthy Subjects | Completed | 2008-10-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00708903 | Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolar… | Phase1 | Breast Cancer | Completed | 2008-05-01 | 2008-07-01 | ClinicalTrials.gov |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subject… | Phase1 | Breast Cancer | Completed | 2008-04-29 | 2018-06-07 | ClinicalTrials.gov |
| NCT00550212 | Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects | Phase1 | Healthy | Completed | 2008-03-01 | 2008-04-01 | ClinicalTrials.gov |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol)… | Phase1 | Advanced Breast Cancer | Completed | 2007-09-11 | 2018-02-07 | ClinicalTrials.gov |
| NCT00498745 | Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects | Phase1 | Healthy | Completed | 2007-07-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00398567 | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herce… | Phase1 | Advanced Breast Cancer | Completed | 2007-04-04 | 2018-03-02 | ClinicalTrials.gov |
| NCT00397046 | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japane… | Phase1 | Tumors | Completed | 2006-11-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00380328 | HKI-272 Ketoconazole Drug Interaction Study | Phase1 | Healthy | Completed | 2006-10-01 | 2006-11-01 | ClinicalTrials.gov |
| NCT00300781 | Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | Phase2 | Breast Neoplasms | Completed | 2006-08-04 | 2018-01-30 | ClinicalTrials.gov |
| NCT00366600 | Study Evaluating HKI-272 Administered to Healthy Subjects | Phase1 | Healthy | Completed | 2006-07-01 | 2006-12-01 | ClinicalTrials.gov |
| NCT00266877 | Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced No… | Phase2 | Carcinoma, Non-Small-Cell Lung | Completed | 2005-12-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00146172 | Study Evaluating HKI-272 in Tumors | Phase1 | Breast Neoplasms | Completed | 2003-11-01 | 2007-01-01 | ClinicalTrials.gov |
Total clinical trials: 55
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | SUSPENDED | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | SUSPENDED | NCT03919292 |
| Pembrolizumab | Other | Phase PHASE2 | GastroEsophageal Cancer | ACTIVE_NOT_RECRUITING | NCT06109467 |
| 5-Fluorouracil + leucovorin | Other | Phase PHASE2 | GastroEsophageal Cancer | ACTIVE_NOT_RECRUITING | NCT06109467 |
| Oxaliplatin | Other | Phase PHASE2 | GastroEsophageal Cancer | ACTIVE_NOT_RECRUITING | NCT06109467 |
| Trastuzumab | Other | Phase PHASE2 | GastroEsophageal Cancer | ACTIVE_NOT_RECRUITING | NCT06109467 |
| Neratinib | Other | Phase PHASE2 | GastroEsophageal Cancer | ACTIVE_NOT_RECRUITING | NCT06109467 |
| Alisertib | Other | Phase PHASE2 | Small Cell Lung Cancer | RECRUITING | NCT06095505 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02334501 |
| Lansoprazole | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02334501 |
| Capecitabine | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | COMPLETED | NCT01128842 |
| Neratinib | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | COMPLETED | NCT01128842 |
| Almac HER-Seq Assay | Other | Preclinical | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer | TERMINATED | NCT03786107 |
| Neratinib | Other | Preclinical | Healthy | COMPLETED | NCT01142063 |
| temsirolimus | Other | Phase PHASE2 | HER2-mutant Non-Small Cell Lung Cancer | COMPLETED | NCT01827267 |
| neratinib | Other | Phase PHASE2 | HER2-mutant Non-Small Cell Lung Cancer | COMPLETED | NCT01827267 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01111825 |
| Temsirolimus | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01111825 |
| lapatinib | Other | Phase PHASE3 | HER2+ Metastatic Breast Cancer (MBC) | COMPLETED | NCT01808573 |
| capecitabine | Other | Phase PHASE3 | HER2+ Metastatic Breast Cancer (MBC) | COMPLETED | NCT01808573 |
| neratinib | Other | Phase PHASE3 | HER2+ Metastatic Breast Cancer (MBC) | COMPLETED | NCT01808573 |
| Cyclophosphamide | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Doxorubicin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Neratinib | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Paclitaxel | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Guardant360 Diagnostic Test | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT03457896 |
| Neratinib | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT03457896 |
| Cetuximab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT03457896 |
| Trastuzumab | Other | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT03457896 |
| Research blood sample | Other | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Tumor biopsy | Other | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Trastuzumab | Other | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Fulvestrant | Other | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Neratinib | Other | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Budesonide | Other | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| Colestipol | Other | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| Loperamide | Other | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| Neratinib | Other | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| T-DM1 | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02236000 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02236000 |
| Loperamide | Other | Phase PHASE2 | HER2 Amplified Breast Cancer | COMPLETED | NCT04366713 |
| Capecitabine | Other | Phase PHASE2 | HER2 Amplified Breast Cancer | COMPLETED | NCT04366713 |
| Neratinib | Other | Phase PHASE2 | HER2 Amplified Breast Cancer | COMPLETED | NCT04366713 |
| Neratinib | Other | Phase PHASE2 | Metastatic Prostate Adenocarcinoma | WITHDRAWN | NCT04781374 |
| Paclitaxel | Other | Phase PHASE2 | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | TERMINATED | NCT01953926 |
| Trastuzumab | Other | Phase PHASE2 | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | TERMINATED | NCT01953926 |
| Fulvestrant | Other | Phase PHASE2 | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | TERMINATED | NCT01953926 |
| Neratinib | Other | Phase PHASE2 | Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | TERMINATED | NCT01953926 |
| Alisertib | Other | Phase PHASE1 | Lung Cancer Metastatic | RECRUITING | NCT04085315 |
| Osimertinib | Other | Phase PHASE1 | Lung Cancer Metastatic | RECRUITING | NCT04085315 |
| Colesevelam | Other | Phase PHASE2 | Early-stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05252988 |
| Loperamide | Other | Phase PHASE2 | Early-stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05252988 |
| Neratinib | Other | Phase PHASE2 | Early-stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05252988 |
| Neratinib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Diphenoxylate/Atropine | Other | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Crofelemer | Other | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Loperamide | Other | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Trastuzumab | Other | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Neratinib | Other | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Ultrasound | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Breast Surgery | Procedure | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Magnetic Resonance Imaging | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Mammogram | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Biospecimen Collection | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Neratinib | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Biopsy of breast | Other | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Endocrine Therapy | Drug | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Fam-Trastuzumab Deruxtecan-Nxki (TDxD) | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05274048 |
| Neratinib Pill | Other | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05274048 |
| Endocrine therapy | Drug | Phase PHASE2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | RECRUITING | NCT06369285 |
| Alisertib | Other | Phase PHASE2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | RECRUITING | NCT06369285 |
| Fulvestrant | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT03289039 |
| Neratinib | Other | Phase PHASE2 | Breast Cancer | TERMINATED | NCT03289039 |
| Ado-Trastuzumab Emtansine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| Capecitabine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| Surgical Resection | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| HKI-272 | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| Pembrolizumab | Other | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| 5-Fluorouracil + leucovorin | Other | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Oxaliplatin | Other | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Trastuzumab | Other | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Neratinib | Other | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Alisertib | Other | Phase PHASE2 | Small Cell Lung Cancer | RECRUITING | NCT06095505 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| Letrozole (L) or Anastrozole (A) | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| Neratinib | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Divalproex Sodium | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Neratinib | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Neratinib | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Capecitabine | Other | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Endocrine therapy | DRUG | Phase PHASE2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | RECRUITING | NCT06369285 |
| Pembrolizumab | DRUG | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| 5-Fluorouracil + leucovorin | DRUG | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Oxaliplatin | DRUG | Phase PHASE2 | GastroEsophageal Cancer | RECRUITING | NCT06109467 |
| Ultrasound | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Breast Surgery | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Mammogram | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Biospecimen Collection | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Biopsy of breast | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Endocrine Therapy | PROCEDURE | Phase PHASE2 | Anatomic Stage I Breast Cancer | RECRUITING | NCT05919108 |
| Fam-Trastuzumab Deruxtecan-Nxki (TDxD) | DRUG | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05274048 |
| Neratinib Pill | DRUG | Phase PHASE1 | Gastric Cancer | RECRUITING | NCT05274048 |
| Colesevelam | DRUG | Phase PHASE2 | Early-stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05252988 |
| Letrozole (L) or Anastrozole (A) | DRUG | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| Neratinib at RP2D | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib at RP2D | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 300 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 200 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Niraparib 100 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 240 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 200 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Neratinib 160 mg | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04502602 |
| Alisertib | DRUG | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | NOT_YET_RECRUITING | NCT07465757 |
| Osimertinib | DRUG | Phase PHASE1 | Lung Cancer Metastatic | RECRUITING | NCT04085315 |
| Divalproex Sodium | DRUG | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT03919292 |
| Cetuximab | DRUG | Phase PHASE2 | Metastatic Colorectal Cancer | UNKNOWN | NCT03457896 |
| EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 | BEHAVIORAL | Phase PHASE1 | Breast Cancer | ACTIVE_NOT_RECRUITING | NCT03377387 |
| Diphenoxylate/Atropine | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Crofelemer | DRUG | Phase PHASE2 | HER2-positive Breast Cancer | COMPLETED | NCT03094052 |
| Budesonide | DRUG | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| Colestipol | DRUG | Phase PHASE2 | Early Stage HER2+ Breast Cancer | COMPLETED | NCT02400476 |
| Loperamide | DRUG | Phase PHASE2 | Early-stage Breast Cancer | ACTIVE_NOT_RECRUITING | NCT05252988 |
| Lansoprazole | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02334501 |
| T-DM1 | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT02236000 |
| temsirolimus | DRUG | Phase PHASE2 | HER2-mutant Non-Small Cell Lung Cancer | COMPLETED | NCT01827267 |
| lapatinib | DRUG | Phase PHASE3 | HER2+ Metastatic Breast Cancer (MBC) | COMPLETED | NCT01808573 |
| capecitabine | DRUG | Phase PHASE3 | HER2+ Metastatic Breast Cancer (MBC) | COMPLETED | NCT01808573 |
| Research blood sample | PROCEDURE | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Tumor biopsy | PROCEDURE | Phase PHASE2 | Breast Neoplasms | COMPLETED | NCT01670877 |
| Fulvestrant | DRUG | Phase PHASE2 | Breast Cancer | TERMINATED | NCT03289039 |
| Ado-Trastuzumab Emtansine | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| Surgical Resection | PROCEDURE | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| Vinorelbine | DRUG | Phase PHASE1 | Advanced Malignant Solid Tumors | COMPLETED | NCT00958724 |
| trastuzumab | DRUG | Phase PHASE1 | Advanced Breast Cancer | COMPLETED | NCT00398567 |
| Cyclophosphamide | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Doxorubicin | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01008150 |
| Trastuzumab | DRUG | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| placebo | OTHER | Phase PHASE3 | Breast Cancer | COMPLETED | NCT00878709 |
| Digoxin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00860223 |
| Temsirolimus | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT01111825 |
| Neratinib (HKI-272) | DRUG | Phase PHASE1 | Hepatic Insufficiency | COMPLETED | NCT00781430 |
| Lapatinib | DRUG | Phase PHASE2 | Advanced Breast Cancer | COMPLETED | NCT00777101 |
| Capecitabine | DRUG | Phase PHASE2 | HER2 Amplified Breast Cancer | COMPLETED | NCT04366713 |
| Neratinib | DRUG | Phase PHASE2 | Breast Cancer | RECRUITING | NCT04886531 |
| Moxifloxacin | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00708903 |
| Placebo | OTHER | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00708903 |
| vinorelbine | DRUG | Phase PHASE1 | Breast Cancer | COMPLETED | NCT00706030 |
| Paclitaxel | DRUG | Phase PHASE2 | Small Cell Lung Cancer ( SCLC ) | NOT_YET_RECRUITING | NCT07465757 |
| HKI-272 | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01494662 |
| neratinib | DRUG | Phase PHASE2 | HER2-mutant Non-Small Cell Lung Cancer | COMPLETED | NCT01827267 |
Total products: 229